Advanced Solid Tumors
Conditions
Brief summary
The overall objective of this Phase 1 study is to evaluate the safety, Pharmacokinetics (PK), and anti-tumor activity of daily oral dosing with GEC255 tablets in subjects with advanced solid tumor with Kirsten Rat Sarcoma (KRAS) p.G12C mutation. To determine the recommended Phase 2 dose (RP2D) based on assessments of multiple dose escalation and expansion in target cohorts.
Detailed description
This First-in-human dose escalation and expansion study of GEC255 tablets in patients with advanced solid tumors with KRAS p.G12C mutation aims to evaluate the safety, tolerability, PK and preliminary efficacy of orally administered GEC255, to determine the MTD, DLT (if exists) and RP2D, and explore the potential biomarker associated with efficacy or drug resistance.
Interventions
DRUGGEC255 tablets
Part 1: Dose escalation After initial starting dose cohort, daily dosages in subsequent cohorts are determined by cohort review committee. Part 2: Dose expansion Daily oral dosage RP2D based on data from Part 1
Sponsors
GenEros Biopharma Hangzhou Ltd
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Has histologically or cytologically confirmed advance tumors with KRAS p.G12C mutation and has poor response to standard of care therapy or intolerant to standard of care therapies (chemotherapy, targeting therapy or immunotherapy). 2. As assessed by the investigator, the subject must have at least one measurable lesion that meets the definition of Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 (subjects with only non-target lesions are allowed to be included in the dose escalation phase) 3. For the second part, subjects with non-small cell lung cancer must have received at least first-line platinum-based chemotherapy and/or immunotherapy /or anti-vascular therapy; subjects with colorectal cancer must have previously received second-line or above therapies and have tumor progression or recurrence. Except for KRAS mutations and other driver gene-positive subjects, they must have received at least first-line approved targeted therapy(if any) and are assessed by researchers that they hardly benefit from existing targeted therapies. 4. Has adequate organ functions, and had no blood transfusion, Erythropoietin (EPO), colony stimulating factor (CSF) or other supportive medical treatment within 14 days prior to the first dosing of GEC255. 5. Has estimated survival period ≥ 3 months. 6. Fertile female subjects must have negative serological test for pregnancy. All subjects must agree to take contraceptive measures from Informed Consent Form (ICF) signing till 3 months after last treatment. 7. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
Exclusion criteria
1. Has received KRAS inhibitor treatment (for second part only). 2. Participated in other interventional clinical trials 4 weeks before enrollment or within 5 half-lives of the trial drug used last time (whichever is longer) . 3. Has had any anticancer treatments, including immunotherapy, chemotherapy, or radiotherapy within 4 weeks prior to the first dose of GEC255. 4. Has gastrointestinal disorder affecting absorption (eg, gastrectomy). 5. Has significant cardiovascular disease. Male subjects with corrected QT interval (QTc) ≥ 450ms, female subject with QTc ≥ 470ms 6. Has primary central nervous system (CNS) tumor; 7. Has unstable brain metastases with meningeal metastasis, spinal cord compression, symptomatic or requiring steroid/anti-epileptic medication 4 weeks before enrollment 8. HIV positive or active infection of hepatitis B virus (HBV), hepatitis C virus (HCV), syphilis, tuberculosis 9. Allergic to ingredients of GEC255; or is currently taking medicines which strongly inhibit CYP3A4.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients experiencing Dose limiting toxicities (DLTs) during the Maximum tolerated dose (MTD) evaluation period for study drug in monotherapy | 28 days | characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drug(Part 1) |
| Determine the recommended Phase II dose (RP2D) and preliminarily to develop a suitable dosing regimen | 24 months | Measured by the number of subjects with dose limiting toxicities |
| Incidence of Treatment-Emergent Adverse Events | 24 months | Characterized by type, frequency, severity (as graded by NCI-CTCAE version 5.0), timing, seriousness |
| Incidence of vital signs abnormalities | 24 months | Characterized by type, frequency, severity (as graded by NCI CTCAE version5.0), and timing,seriousness |
| Incidence of ECG (PR interval, QRS complex, QT corrected interval prolonged, and QT interval corrected using Fridericia's formula) abnormalities | 24 months | Characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing |
| Incidence of laboratory abnormalities | 24 months | Characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| All study parts,Maximum concentration (Cmax) of GEC255 | Up to 24 months | All study parts,Maximum concentration (Cmax) of GEC255 |
| All study parts,Time to maximum plasma concentration (Tmax) of GEC255 | Up to 24 months | All study parts,Time to maximum plasma concentration (Tmax) of GEC255 |
| Overall response rate (ORR) per RECIST v1.1, by treatment | 24 months | Overall response rate is defined as the proportion of patients with a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) according to RECIST 1.1, and will be summarized along with the corresponding 95% exact binomial confidence interval (CI) |
| Disease Control Rate (DCR) per RECIST v1.1 | 24 months | The disease control rate is calculated as the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease. It will be summarized along with the corresponding 95% exact CI |
| All study parts, Area under the plasma concentration-time curve from time zero to time t(AUC0-t) of GEC255 | Up to 24 months | All study parts, Area under the plasma concentration-time curve from time zero to time t(AUC0-t) of GEC255 |
| Progression-free survival (PFS) per RECIST v1.1 | 24 months | Per RECIST 1.1, PFS is defined as the time from the date of start of treatment to the date of the first documented progression. If patient has not had an event, PFS will be censored at the date of last adequate tumor assessment |
| To evaluate Overall Survival (OS) following initiation of GEC255 | 24 months | OS is defined as the time from the date of start of treatment to the date of the death |
| Evaluation of gene mutations profiles | 24 months | Evaluation of gene mutations profiles including KRAS, STK11, KEAP1 etc in cell-free DNA (cfDNA) samples by Next-generation sequencing (NGS) method at various time points during treatment until disease progression |
| Duration of Response (DOR) per RECIST v1.1 | 24 months | Duration of response is defined as the time from the date of the first documented response (CR or PR), to the date of first documented progression, or death due any cause. Estimates will use Kaplan-Meier method, and median DOR and corresponding 95% CI will be presented |
| All study parts,Area under the plasma concentration-time curve from time zero to time infinity(AUC0-∞) of GEC255 | Up to 24 months | All study parts,Area under the plasma concentration-time curve from time zero to time infinity(AUC0-∞) of GEC255 |
| All study parts,Area under the plasma concentration-time curve over dosing interval (AUCtau) of GEC255 | Up to 24 months | All study parts,Area under the plasma concentration-time curve over dosing interval (AUCtau) of GEC255 |
| All study parts,Apparent plasma clearance of drug after extravascular administration(CL/F) of GEC255 | Up to 24 months | All study parts,Apparent plasma clearance of drug after extravascular |
| All study parts,Terminal half-life(t½) of GEC255 | Up to 24 months | All study parts,Terminal half-life(t½) of GEC255 |
| All study parts,Apparent Volume of Distribution(VZ/F) of GEC255 | Up to 24 months | All study parts,Apparent Volume of Distribution(VZ/F) of GEC255 |
Countries
China
Contacts
Primary ContactXinYu Liu, PhD
Outcome results
None listed